185 related articles for article (PubMed ID: 2787679)
1. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease.
Tötterman TH; Carlsson M; Simonsson B; Bengtsson M; Nilsson K
Blood; 1989 Aug; 74(2):786-92. PubMed ID: 2787679
[TBL] [Abstract][Full Text] [Related]
2. CD4, CD8 and NK subsets in B-CLL.
Vuillier F; Tortevoye P; Binet JL; Dighiero G
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):331-4. PubMed ID: 3265505
[TBL] [Abstract][Full Text] [Related]
3. Regeneration of functional and activated NK and T sub-subset cells in the marrow and blood after autologous bone marrow transplantation: a prospective phenotypic study with 2/3-color FACS analysis.
Bengtsson M; Tötterman TH; Smedmyr B; Festin R; Oberg G; Simonsson B
Leukemia; 1989 Jan; 3(1):68-75. PubMed ID: 2535882
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic and DNA genotypic analysis of T-cell and NK-cell subpopulations in patients with B-cell chronic lymphocytic leukaemia (B-CLL).
Frolova EA; Richards SJ; Jones RA; Rawstron A; Master PS; Teasdale J; Short M; Jack AS; Scott CS
Leuk Lymphoma; 1995 Jan; 16(3-4):307-18. PubMed ID: 7719238
[TBL] [Abstract][Full Text] [Related]
5. Differences in blood T and NK cell populations between chronic lymphocytic leukemia of B cell type (B-CLL) and monoclonal B-lymphocytosis of undetermined significance (B-MLUS).
Kimby E; Mellstedt H; Nilsson B; Björkholm M; Holm G
Leukemia; 1989 Jul; 3(7):501-4. PubMed ID: 2471902
[TBL] [Abstract][Full Text] [Related]
6. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia.
Mackus WJ; Frakking FN; Grummels A; Gamadia LE; De Bree GJ; Hamann D; Van Lier RA; Van Oers MH
Blood; 2003 Aug; 102(3):1057-63. PubMed ID: 12689926
[TBL] [Abstract][Full Text] [Related]
7. Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities.
Reyes E; Prieto A; Carrion F; Garcia-Suarez J; Esquivel F; Alvarez-Mon M
Am J Hematol; 1997 Aug; 55(4):175-82. PubMed ID: 9257876
[TBL] [Abstract][Full Text] [Related]
8. Blood and liver-infiltrating lymphocytes in primary biliary cirrhosis: increase in activated T and natural killer cells and recruitment of primed memory T cells.
Björkland A; Festin R; Mendel-Hartvig I; Nyberg A; Lööf L; Tötterman TH
Hepatology; 1991 Jun; 13(6):1106-11. PubMed ID: 2050330
[TBL] [Abstract][Full Text] [Related]
9. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
[TBL] [Abstract][Full Text] [Related]
10. T cell malignancy in Richter's syndrome presenting as hyper IgM. Induction and characterization of a novel CD3+, CD4-, CD8+ T cell subset from phytohemagglutinin-stimulated patient's CD3+, CD4+, CD8+ leukemic T cells.
Raziuddin S; Assaf HM; Teklu B
Eur J Immunol; 1989 Mar; 19(3):469-74. PubMed ID: 2523311
[TBL] [Abstract][Full Text] [Related]
11. The absence of correlation between immunoregulatory T cells and induced lymphoproliferative response in treated B-chronic lymphocytic leukemia patients.
Milosević D; Marinković M; Colović M; Jelić S
Panminerva Med; 1999 Jun; 41(2):93-7. PubMed ID: 10479904
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
[TBL] [Abstract][Full Text] [Related]
13. Quantitative differences in CD8+ lymphocytes, CD4/CD8 ratio, NK cells, and HLA-DR(+)-activated T cells of racially different male populations.
Shahabuddin S
Clin Immunol Immunopathol; 1995 May; 75(2):168-70. PubMed ID: 7704975
[TBL] [Abstract][Full Text] [Related]
14. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
[TBL] [Abstract][Full Text] [Related]
15. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease.
Huergo-Zapico L; Acebes-Huerta A; Gonzalez-Rodriguez AP; Contesti J; Gonzalez-García E; Payer AR; Villa-Alvarez M; Fernández-Guizán A; López-Soto A; Gonzalez S
PLoS One; 2014; 9(10):e108326. PubMed ID: 25286418
[TBL] [Abstract][Full Text] [Related]
16. A low blood lymphocyte count is associated with an expansion of activated cytotoxic lymphocytes in patients with B-cell chronic lymphocytic leukaemia.
Martín AP; Martín ER; García-Suárez J; Arriagada FC; del Puerto Hernandez-Fuentes M; Vilaplana JC; Alvarez-Mon Soto M
Eur J Haematol; 1997 Aug; 59(2):89-99. PubMed ID: 9293856
[TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia.
Blanco G; Puiggros A; Sherry B; Nonell L; Calvo X; Puigdecanet E; Chiu PY; Kieso Y; Ferrer G; Palacios F; Arnal M; Rodríguez-Rivera M; Gimeno E; Abella E; Rai KR; Abrisqueta P; Bosch F; Calon A; Ferrer A; Chiorazzi N; Espinet B
Exp Hematol; 2021 Mar; 95():68-80. PubMed ID: 33421548
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.
Karlsson FA; Tötterman TH
Clin Exp Immunol; 1988 Nov; 74(2):258-63. PubMed ID: 2906281
[TBL] [Abstract][Full Text] [Related]
19. Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia.
Bojarska-Junak A; Rolinski J; Wasik-Szczepaneko E; Kaluzny Z; Dmoszynska A
Haematologica; 2002 May; 87(5):490-9. PubMed ID: 12010662
[TBL] [Abstract][Full Text] [Related]
20. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Winqvist M; Mozaffari F; Palma M; Eketorp Sylvan S; Hansson L; Mellstedt H; Österborg A; Lundin J
Cancer Immunol Immunother; 2017 Jan; 66(1):91-102. PubMed ID: 27815572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
